Last updated: September 23, 2026
Sotagliflozin, marketed in the United States as Inpefa by Lexicon Pharmaceuticals, is a dual SGLT1/SGLT2 inhibitor approved by the FDA in May 2023. Its commercial opportunity is concentrated in heart failure and high-risk chronic kidney disease rather than routine glucose control. Early sales have been modest because Lexicon is competing against Jardiance, Farxiga, and other established SGLT2 inhibitors with broader prescribing familiarity, larger commercial infrastructure, and entrenched payer access.
The drug’s principal value is clinical differentiation in patients with heart failure or type 2 diabetes, chronic kidney disease, and cardiovascular risk factors. Its principal commercial weaknesses are a narrow FDA positioning, late market entry, limited sales infrastructure, gastrointestinal tolerability concerns linked to SGLT1 inhibition, and intense competition from products already approved across diabetes, heart failure, and CKD.
What is sotagliflozin and how does Inpefa work?
Sotagliflozin inhibits both SGLT2 and SGLT1. SGLT2 inhibition reduces renal glucose and sodium reabsorption. SGLT1 inhibition affects glucose and sodium absorption in the intestine and kidney.
The FDA approved Inpefa tablets in 200 mg and 400 mg strengths. The recommended starting dose is 200 mg once daily, with an increase to 400 mg once daily when tolerated.[1]
Unlike Jardiance and Farxiga, Inpefa’s commercial label is not centered on glycemic control. The approved indication is cardiovascular and heart-failure risk reduction in:
- Adults with heart failure, or
- Adults with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
The label covers reduction in the risk of cardiovascular death, hospitalization for heart failure, and urgent heart-failure visits.[1]
What clinical evidence supports sotagliflozin?
Sotagliflozin’s FDA approval was based mainly on the SOLOIST-WHF and SCORED trials.
| Trial |
Patient population |
Primary or key outcome |
Reported result |
| SOLOIST-WHF |
Patients with type 2 diabetes recently hospitalized for worsening heart failure |
Cardiovascular death, heart-failure hospitalization, or urgent heart-failure visit |
33% relative risk reduction versus placebo |
| SCORED |
Patients with type 2 diabetes, CKD, and cardiovascular risk |
Cardiovascular death, heart-failure hospitalization, or urgent heart-failure visit |
26% relative risk reduction versus placebo |
The results support use across reduced, mildly reduced, and preserved ejection-fraction settings, although treatment decisions remain dependent on patient characteristics, renal function, volume status, and competing SGLT2 options.[2][3]
Sotagliflozin’s safety profile is broadly consistent with the SGLT inhibitor class. Important risks include ketoacidosis, volume depletion, genital mycotic infections, urinary tract infections, hypoglycemia when combined with insulin or insulin secretagogues, and diarrhea. Diarrhea is commercially relevant because intestinal SGLT1 inhibition creates a tolerability distinction from predominantly SGLT2-selective products.[1]
What is the FDA regulatory status of sotagliflozin?
Inpefa received FDA approval on May 26, 2023. The approval followed an earlier regulatory setback.
| Regulatory event |
Date |
Commercial relevance |
| FDA cardiovascular advisory committee review |
2021 |
Committee voted against approval in the initial heart-failure setting |
| SOLOIST-WHF and SCORED publication |
2021 |
Established outcome evidence in heart failure and CKD |
| FDA approval of Inpefa |
May 26, 2023 |
Created the U.S. commercial market |
| U.S. commercial launch |
2023 |
Lexicon began specialty and cardiovascular commercialization |
The initial FDA review was influenced by trial design, statistical considerations, and the limited number of events available for certain endpoints. Lexicon subsequently obtained approval for a broader cardiovascular-risk-reduction indication rather than an approval focused solely on glycemic control.
As of mid-2024, the United States remained the principal commercial market. Sotagliflozin did not have the global regulatory reach of empagliflozin or dapagliflozin.
What is the market size for sotagliflozin?
The addressable population is large, but the immediately reachable market is narrower.
Sotagliflozin can theoretically compete in several populations:
- Patients with heart failure across ejection-fraction categories.
- Patients with type 2 diabetes and CKD who have elevated cardiovascular risk.
- Patients recently hospitalized for worsening heart failure.
- Patients who require additional cardiovascular-risk reduction despite standard therapy.
The practical market is constrained by prescribing overlap. Many eligible patients already receive Jardiance or Farxiga because those products have:
- Established diabetes indications.
- Broad heart-failure indications.
- CKD indications.
- Extensive guideline adoption.
- Large payer and physician-support programs.
- Longer commercial histories.
The most attractive segment for Inpefa is not the entire SGLT2 market. It is the subset of patients in whom clinicians value the SOLOIST-WHF and SCORED evidence, particularly those with recent heart-failure hospitalization or a combination of type 2 diabetes, CKD, and cardiovascular risk.
How does sotagliflozin compare with Jardiance and Farxiga?
| Attribute |
Inpefa |
Jardiance |
Farxiga |
| Active ingredient |
Sotagliflozin |
Empagliflozin |
Dapagliflozin |
| Mechanism |
Dual SGLT1/SGLT2 |
Primarily SGLT2 |
Primarily SGLT2 |
| U.S. sponsor |
Lexicon |
Boehringer Ingelheim and Eli Lilly |
AstraZeneca |
| FDA approval year for current product |
2023 |
2014 |
2014 |
| Diabetes indication |
Not the core Inpefa label |
Yes |
Yes |
| Heart-failure use |
Yes |
Yes |
Yes |
| CKD use |
Cardiovascular-risk population with type 2 diabetes and CKD |
Yes |
Yes |
| Commercial maturity |
New entrant |
Established |
Established |
| Key differentiation |
Dual inhibition and outcome data in recently hospitalized HF |
Large cardiovascular evidence base and commercial scale |
Broad HF and CKD positioning |
| Main weakness |
Limited market access and late entry |
Class and label overlap |
Class and label overlap |
The competitive issue is less whether sotagliflozin has clinical activity. It does. The issue is whether its evidence creates enough incremental value to displace a product already embedded in the treatment pathway.
What has been Lexicon’s financial trajectory for sotagliflozin?
Inpefa sales began from a low base in 2023. Lexicon’s launch was a controlled specialty-pharma commercialization rather than a large primary-care launch.
Revenue development
| Period |
Financial position |
Interpretation |
| Pre-2023 |
No commercial sotagliflozin revenue |
Lexicon operated primarily through development programs, partnerships, and financing |
| 2023 |
Initial Inpefa product revenue after May approval |
Launch year with limited commercial duration |
| First half of 2024 |
Product revenue remained low relative to the opportunity |
Uptake was still early and insufficient to transform corporate revenue |
| 2024 outlook |
Dependent on formulary expansion, cardiology adoption, and prescription growth |
Commercial execution became more important than regulatory progress |
Lexicon’s near-term financial model depended on prescription growth rather than a large upfront licensing payment. The company faced continuing selling, general, and administrative costs associated with the launch, while product revenue remained too small to support rapid operating leverage.
The financial trajectory therefore had three phases:
- Development-stage funding and partnership dependence.
- Early commercial launch with low initial product revenue.
- A potential scale-up phase requiring meaningful formulary access and specialist adoption.
The principal financial risk was the gap between the size of the eligible population and the speed at which Lexicon could convert that population into reimbursed prescriptions.
What revenue exposure does Inpefa create for Lexicon?
Inpefa is strategically important because Lexicon has few products with comparable near-term commercial potential. That concentration creates operating leverage in both directions:
- Strong prescription growth could materially improve revenue visibility.
- Slow adoption could prolong cash burn and force additional financing or partnership activity.
- A commercial underperformance would affect Lexicon more severely than it would a diversified pharmaceutical company.
- A successful launch could support later partnering, regional licensing, or expanded cardiovascular development.
Inpefa was not a large revenue contributor at the time of launch. Its value was based on future penetration, not established sales.
What patents protect sotagliflozin and when does it lose exclusivity?
Sotagliflozin is protected by a combination of composition-of-matter, pharmaceutical-composition, formulation, and method-of-use rights. The practical exclusivity period depends on the specific patent claims, patent-term adjustment, patent-term extension, FDA regulatory exclusivity, and any Orange Book listings.
The principal U.S. exclusivity milestones are:
| Protection |
Expected timing |
Commercial effect |
| FDA new chemical entity exclusivity |
Through approximately May 2028 |
Blocks submission of an ANDA relying on the reference product during the NCE period |
| Listed patents |
Potentially extending beyond NCE exclusivity |
May require generic applicants to certify or wait for expiration |
| Pediatric exclusivity |
Not established as a commercial assumption |
Would add six months only if awarded |
| Patent-term extension |
Not established as a commercial assumption |
Could extend an eligible patent by up to five years, subject to statutory limits |
The most important patent risk is not simply the earliest expiration date. Generic entry depends on:
- Which patents are listed in the Orange Book.
- Whether claims cover the active ingredient, formulation, dosage, or method of use.
- Whether a generic applicant files Paragraph IV certifications.
- Whether Lexicon sues within the statutory period.
- Whether litigation produces a 30-month stay.
- Whether settlement terms permit an agreed launch date.
What formulations and methods of use are protected?
Potentially valuable claim categories include:
- Sotagliflozin pharmaceutical compositions.
- Oral tablet formulations.
- Dosing regimens for heart failure.
- Use in patients with type 2 diabetes and CKD.
- Use after hospitalization for worsening heart failure.
- Cardiovascular-risk-reduction methods.
- Combination treatment with standard heart-failure therapy.
Method-of-use patents may be commercially important even when a generic product can enter for an unpatented indication. A generic company can seek a label that omits patented uses, although enforcement becomes fact-specific if physicians prescribe the product for protected indications.
The patent estate is stronger if it includes composition claims that remain valid after the FDA’s five-year NCE period. It is weaker if protection depends mainly on narrow method-of-use or formulation claims that can be designed around.
What is the Orange Book status of Inpefa?
Inpefa is an FDA-approved small-molecule drug and is eligible for Orange Book listing of applicable patents. The FDA Orange Book is the key public source for approved-product patents, therapeutic-equivalence evaluations, and generic-application certifications.[4]
The commercial implications are:
- An ANDA applicant must address listed patents.
- A Paragraph IV certification can trigger patent litigation.
- A timely patent suit can delay approval through the statutory 30-month period, subject to court decisions and regulatory events.
- An authorized generic or settlement could alter the effective launch date.
- Non-listed patents may still be enforceable but do not create the same ANDA-specific litigation framework.
No publicly established high-volume Paragraph IV challenge had materially changed the Inpefa market position through mid-2024. The earliest realistic generic pressure was more likely to emerge as the NCE period approached, unless a patent challenger pursued an early invalidity or non-infringement strategy.
Which companies are challenging sotagliflozin?
No major commercial generic entrant had established a visible market position for sotagliflozin through mid-2024. The likely challenger universe includes:
- Large generic manufacturers with cardiovascular portfolios.
- Indian and European ANDA applicants.
- Specialty generic companies targeting niche cardiovascular products.
- Companies evaluating an authorized-generic or settlement opportunity.
The absence of an early challenge does not eliminate later Paragraph IV risk. Generic applicants generally have greater incentive to challenge when:
- Prescription volume becomes measurable.
- Product pricing supports a profitable launch.
- Patent expiration approaches.
- Formulation and manufacturing processes are reproducible.
- The reference product has an established reimbursement position.
What licensing deals affect sotagliflozin?
Sotagliflozin was developed through a prior Lexicon collaboration with Sanofi. The collaboration included diabetes-focused development and commercialization work, but the relationship ended and rights returned to Lexicon. Lexicon subsequently retained control of Inpefa’s U.S. commercialization.
The termination had two commercial consequences:
- Lexicon retained greater long-term economics if the product succeeded.
- Lexicon also assumed the cost and execution risk of commercialization.
The company therefore lacked the immediate scale of a global cardiovascular partner. A future licensing transaction could provide capital, sales infrastructure, or regional access, but it could also reduce Lexicon’s net economics and strategic control.
What litigation affects sotagliflozin?
The central litigation risk is expected to be generic patent litigation rather than a major branded-versus-branded dispute.
Key potential litigation categories are:
- Paragraph IV ANDA litigation.
- Patent validity challenges under inter partes review.
- Infringement actions involving formulation or method-of-use claims.
- Contract disputes involving earlier development or commercialization partners.
- Patent ownership or inventorship disputes.
Through mid-2024, the commercial story was driven more by launch execution and market access than by active generic litigation.
How strong is the sotagliflozin patent estate?
The estate is commercially useful but not automatically dominant.
Strengths
- Sotagliflozin has a five-year FDA NCE exclusivity period.
- A dual-mechanism product can support distinct method-of-use claims.
- Heart-failure and CKD indications provide multiple potential claim sets.
- Post-hospitalization treatment may create narrower but clinically meaningful use claims.
- Lexicon controls the commercial product in the United States.
Weaknesses
- SGLT inhibitors are a crowded technical field.
- Some method-of-use claims may face obviousness and enablement challenges.
- Generic products can pursue label carve-outs.
- The commercial value of later patents depends on actual prescribing behavior.
- The product entered after leading SGLT2 brands had already established treatment norms.
Patent strength should therefore be assessed claim by claim. The most valuable rights are valid composition or broad treatment claims that cover commercially important patients through the period when Inpefa achieves peak sales.
What generic launch scenarios exist for Inpefa?
Three launch scenarios are commercially plausible.
Scenario 1: Patent-protected launch after the main protection period
A generic applicant waits for NCE and relevant patent protection to expire. This produces the cleanest entry path but delays competition and preserves Lexicon’s pricing opportunity.
Scenario 2: Paragraph IV challenge and litigation
A generic applicant certifies that listed patents are invalid, unenforceable, or not infringed. Lexicon files suit, potentially creating a 30-month stay. The outcome depends on claim construction, validity, infringement, and settlement terms.
Scenario 3: Settlement with an agreed entry date
Lexicon and a challenger agree to a future generic launch. The agreement may include a license, supply arrangement, or authorized-generic provision. The economic effect depends on the entry date and the level of competition permitted.
The commercial downside of early generic entry is amplified because Lexicon’s product revenue base is small. A launch before peak penetration could prevent the company from recovering the cost of commercialization.
What is the commercial outlook for sotagliflozin?
Sotagliflozin has a credible clinical position but a difficult commercial one.
The opportunity is strongest where physicians recognize the evidence from SOLOIST-WHF and SCORED, especially in patients with recent heart-failure hospitalization, type 2 diabetes, CKD, and high cardiovascular risk. The product can also benefit from continued expansion of SGLT inhibitor use in heart failure and CKD.
The main barriers are:
- Late entry into a mature SGLT2 category.
- Strong competition from Jardiance and Farxiga.
- Limited label relevance for routine diabetes treatment.
- Need for cardiology and nephrology adoption.
- Payer step edits and formulary preference.
- Diarrhea and other tolerability concerns.
- Lexicon’s limited commercial scale.
- Potential future generic and patent challenges.
A successful trajectory requires sustained prescription growth, improved payer coverage, guideline visibility, and a commercial partner with stronger cardiovascular reach. Without those factors, Inpefa is more likely to remain a niche cardiovascular product than become a broad SGLT franchise.
Key Takeaways
- Inpefa is the U.S. brand for sotagliflozin, a dual SGLT1/SGLT2 inhibitor approved in May 2023.
- The FDA label targets heart failure and cardiovascular-risk reduction in patients with type 2 diabetes, CKD, and other risk factors.
- SOLOIST-WHF and SCORED provide meaningful clinical differentiation.
- Jardiance and Farxiga remain the main commercial competitors because they have broader labels and stronger market infrastructure.
- Lexicon’s early product revenue was modest and did not yet support a large commercial scale-up.
- FDA NCE exclusivity is expected to run through approximately May 2028, subject to the applicable regulatory record.
- Patent value depends on the scope and durability of composition, formulation, and method-of-use claims.
- No major generic challenge had materially altered the U.S. market through mid-2024.
- The largest commercial risks are payer access, physician switching behavior, limited sales scale, tolerability, and eventual generic entry.
- Inpefa’s upside depends on becoming a differentiated heart-failure and CKD product rather than competing as a general diabetes drug.
FAQs About Sotagliflozin Market and Patent Risk
Is sotagliflozin better than empagliflozin or dapagliflozin?
There is no established broad superiority finding. Sotagliflozin has dual SGLT1/SGLT2 activity and outcome data in specific high-risk populations, while empagliflozin and dapagliflozin have broader commercial labels and longer clinical adoption.
Is Inpefa approved for blood-sugar control?
The Inpefa label is focused on cardiovascular and heart-failure risk reduction. It is not positioned primarily as a conventional glucose-lowering product in the way Jardiance and Farxiga are.
Can a generic manufacturer launch sotagliflozin before 2028?
A generic launch before the end of NCE exclusivity would generally require a regulatory and legal pathway that does not rely on the protected reference-product approval, or a successful challenge to applicable protection. The practical timing also depends on Orange Book patents and litigation.
Does sotagliflozin have biosimilar risk?
No. Sotagliflozin is a small-molecule drug, so its relevant competitors are generic manufacturers filing ANDAs, not biosimilar developers using the biologics pathway.
What would most improve Inpefa’s commercial outlook?
The highest-impact factors would be broader payer coverage, inclusion in treatment guidelines, stronger adoption after heart-failure hospitalization, expanded commercial partnerships, and evidence that differentiates sotagliflozin from Jardiance and Farxiga in defined patient groups.
References
-
U.S. Food and Drug Administration. (2023). Inpefa (sotagliflozin) prescribing information. FDA.
-
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Ponikowski, P., & SOLOIST-WHF Trial Investigators. (2021). Sotagliflozin in patients with diabetes and recent worsening heart failure. New England Journal of Medicine, 384(2), 117-128.
-
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., & SCORED Investigators. (2021). Sotagliflozin in patients with diabetes and chronic kidney disease. New England Journal of Medicine, 384(2), 129-139.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Lexicon Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023). FDA approves new treatment to reduce risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in certain adults. FDA.
